MRX-2843 trihydrochloride

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 577787

CAS#: 2498541-94-7

Description: MRX-2843 trihydrochloride is a potent and orally active MERTK and FLT3 inhibitor.

Chemical Structure

img
MRX-2843 trihydrochloride
CAS# 2498541-94-7
Instruction

Theoretical Analysis

MedKoo Cat#: 577787
Name: MRX-2843 trihydrochloride
CAS#: 2498541-94-7
Chemical Formula: C29H43Cl3N6O
Exact Mass: 596.26
Molecular Weight: 598.050
Elemental Analysis: C, 58.24; H, 7.25; Cl, 17.78; N, 14.05; O, 2.68

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: MRX-2843 trihydrochloride; MRX-2843 3HCl

IUPAC/Chemical Name: (1r,4r)-4-(2-((2-cyclopropylethyl)amino)-5-(4-((4-methylpiperazin-1-yl)methyl)phenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclohexan-1-ol trihydrochloride

InChi Key: YNKJODWPAGVMNU-WNUVTMPVSA-N

InChi Code: 1S/C29H40N6O.3ClH/c1-33-14-16-34(17-15-33)19-22-4-6-23(7-5-22)27-20-35(24-8-10-25(36)11-9-24)28-26(27)18-31-29(32-28)30-13-12-21-2-3-21;;;/h4-7,18,20-21,24-25,36H,2-3,8-17,19H2,1H3,(H,30,31,32);3*1H/t24-,25-;;;

SMILES Code: Cl.Cl.Cl.CN1CCN(Cc2ccc(cc2)c3cn([C@@H]4CC[C@@H](O)CC4)c5nc(NCCC6CC6)ncc35)CC1

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: To be determined

Shelf Life: >2 years if stored properly

Drug Formulation: To be determined

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 598.05 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1. Minson KA, Smith CC, DeRyckere D, Libbrecht C, Lee-Sherick AB, Huey MG, Lasater EA, Kirkpatrick GD, Stashko MA, Zhang W, Jordan CT, Kireev D, Wang X, Frye SV, Earp HS, Shah NP, Graham DK. The MERTK/FLT3 inhibitor MRX-2843 overcomes resistance-conferring FLT3 mutations in acute myeloid leukemia. JCI Insight. 2016 Mar;1(3):e85630. doi: 10.1172/jci.insight.85630. PMID: 27158668; PMCID: PMC4855528.

2. Su YT, Butler M, Zhang M, Zhang W, Song H, Hwang L, Tran AD, Bash RE, Schorzman AN, Pang Y, Yu G, Zamboni WC, Wang X, Frye SV, Miller CR, Maric D, Terabe M, Gilbert MR, Earp Iii HS, Wu J. MerTK inhibition decreases immune suppressive glioblastoma-associated macrophages and neoangiogenesis in glioblastoma microenvironment. Neurooncol Adv. 2020 Jun 3;2(1):vdaa065. doi: 10.1093/noajnl/vdaa065. PMID: 32642716; PMCID: PMC7324055.